Pipeline
Six programs, every phase counted from data.
Filter by therapy area and modality. The filters are kept in the URL, so you can bookmark or share a view.
Therapy area
Modality
Phase
6 programs
Program
Discovery 1
Preclinical 1
Phase 1 1
Phase 2 3
Phase 3 0
Filed 0
No programs match these filters.
Try removing a filter or reset to see all 6 programs.
| Program | Indication | Therapy | Modality | Target | Phase |
|---|---|---|---|---|---|
| BPC-101 | HR-positive / HER2-negative metastatic breast cancer | oncology | small molecule | Cyclin-dependent kinase 4/6 (CDK4/6) | phase 2 |
| BPC-203 | Relapsed/refractory B-cell lymphoma | oncology | biologic | Cluster of differentiation 19 (CD19) | phase 1 |
| BPC-305 | Systemic lupus erythematosus | immunology | small molecule | Tyrosine kinase 2 (TYK2) | preclinical |
| BPC-402 | EGFR-mutant non-small cell lung cancer | oncology | adc | Human epidermal growth factor receptor 3 (HER3) | phase 2 |
| BPC-509 | Phenylketonuria (PAH deficiency) | rare disease | gene therapy | Phenylalanine hydroxylase (PAH) | discovery |
| BPC-612 | Moderate to severe ulcerative colitis | immunology | biologic | Tumor necrosis factor-like ligand 1A (TL1A) | phase 2 |
Each program carries an investigational, not approved disclaimer on its detail page.